Want to see HK:2367 full AI Analyst Report?
Top Page
Giant Biogene Holding Co. Ltd.
(2367)
Select Model
Select Model
Rating:71Outperform
Price Target:
HK$21.50
▼(-25.24% Downside)
Action:Reiterated
Date:08/30/26
The score is driven primarily by strong underlying financial quality (high profitability and very low leverage) and a reasonable valuation (P/E ~14.7 with a ~2.3% dividend yield). These positives are partially offset by weak technicals, with the stock trading below key moving averages and bearish momentum indicators (negative MACD, RSI ~40).
Positive Factors
Exceptional Profitability
Exceptionally high gross, net, and operating margins indicate that the company retains substantial economics in its biotechnology ingredients and consumer-products operations. This profitability provides resources for research, brand development, and reinvestment while offering resilience through moderate demand fluctuations.
Negative Factors
Revenue Contraction
The 2025 revenue decline marks a clear reversal from the company’s earlier rapid expansion and indicates weaker near-term demand or slower customer adoption. If contraction persists, it could reduce operating leverage, constrain reinvestment capacity, and make recovery in earnings growth more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Exceptional Profitability
Exceptionally high gross, net, and operating margins indicate that the company retains substantial economics in its biotechnology ingredients and consumer-products operations. This profitability provides resources for research, brand development, and reinvestment while offering resilience through moderate demand fluctuations.
Read all positive factors
Giant Biogene Holding Co. Ltd. (2367) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$20.76B
Dividend Yield3.15%
Average Volume (3M)3.34M
Price to Earnings (P/E)10.8
Beta (1Y)1.04
Revenue Growth-9.65%
EPS Growth-25.51%
CountryHK
Employees2,319
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)1.56
Shares Outstanding1,061,704,000
10 Day Avg. Volume5,136,827
30 Day Avg. Volume3,338,103
Financial Highlights & Ratios
PEG Ratio-1.27
Price to Book (P/B)3.19
Price to Sales (P/S)5.73
P/FCF Ratio21.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$40.59Price Target Upside41.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)1.82
Revenue Forecast (FY)HK$6.06B
Giant Biogene Holding Co. Ltd. Business Overview & Revenue Model
Company Description
Giant Biogene Holding Co., Ltd. operates as an investment holding entity, primarily engaged in the research, development, production, and sale of beauty and wellness products based on bioactive materials throughout the People's Republic of China. ...
Giant Biogene Holding Co. Ltd. Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.28B | 5.52B | 5.54B | 3.52B | 2.36B | 1.55B |
| Gross Profit | 4.18B | 4.43B | 4.55B | 2.95B | 2.00B | 1.35B |
| EBITDA | 1.77B | 2.20B | 2.33B | 1.78B | 1.21B | 934.78M |
| Net Income | 1.66B | 1.91B | 2.06B | 1.45B | 1.00B | 828.13M |
Balance Sheet | ||||||
| Total Assets | 10.24B | 10.85B | 8.04B | 4.97B | 3.14B | 7.88B |
| Cash, Cash Equivalents and Short-Term Investments | 7.39B | 8.29B | 5.86B | 3.78B | 2.20B | 7.26B |
| Total Debt | 12.25M | 9.69M | 6.71M | 2.73M | 2.59M | 7.68B |
| Total Liabilities | 872.40M | 917.03M | 918.14M | 602.03M | 301.19M | 6.86B |
| Stockholders Equity | 9.36B | 9.92B | 7.11B | 4.36B | 2.83B | 1.02B |
Cash Flow | ||||||
| Free Cash Flow | 1.83B | 1.48B | 1.79B | 1.42B | 778.39M | 581.21M |
| Operating Cash Flow | 2.07B | 1.90B | 2.04B | 1.65B | 931.64M | 692.40M |
| Investing Cash Flow | -1.33B | -471.99M | -1.11B | -527.28M | -858.74M | 1.56B |
| Financing Cash Flow | -2.57B | 892.40M | 582.95M | 51.81M | -5.79B | 4.48B |
Giant Biogene Holding Co. Ltd. Technical Analysis
Negative
28.76
Price Trends
24.26
Negative
26.06
Negative
27.88
Negative
Market Momentum
-1.26
Positive
27.14
Positive
6.99
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2367, the sentiment is Negative. The current price of 28.76 is above the 20-day moving average (MA) of 22.14, above the 50-day MA of 24.26, and above the 200-day MA of 27.88, indicating a bearish trend. The MACD of -1.26 indicates Positive momentum. The RSI at 27.14 is Positive, neither overbought nor oversold. The STOCH value of 6.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2367.
Giant Biogene Holding Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$9.03B | 11.18 | 25.77% | 6.20% | 23.19% | -22.44% | |
71 Outperform | HK$20.76B | 10.77 | 17.22% | 3.15% | -9.65% | -25.51% | |
66 Neutral | HK$484.68M | 5.70 | 6.06% | 9.77% | 2.24% | -39.98% | |
65 Neutral | HK$24.47B | 8.48 | 10.98% | 7.60% | 2.19% | 10.78% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | HK$880.92M | -15.33 | -12.81% | 0.53% | 13.43% | 7.72% | |
46 Neutral | HK$13.52B | -148.17 | -1.21% | 4.86% | -2.44% | 81.73% |
* Consumer Defensive Sector Average
HK:2367
Giant Biogene Holding Co. Ltd.
19.80
-15.68
-44.19%
HK:1044
Hengan International Group Co
21.08
-4.32
-17.01%
HK:3828
Ming Fai International Holdings
0.67
-0.24
-26.84%
HK:0157
Natural Beauty Bio-Technology
0.44
-0.10
-18.52%
HK:2145
Shanghai Chicmax Cosmetics Co., Ltd. Class H
22.66
-61.48
-73.07%
HK:6993
Blue Moon Group Holdings Ltd.
2.43
-0.38
-13.62%
Giant Biogene Holding Co. Ltd. Corporate Events
Giant Biogene’s Interim Profit Drops Amid Rising Expenses
Aug 18, 2026
Giant Biogene reported a decline in performance for the six months ended 30 June 2026, with revenue slipping 6.3% year on year to RMB 2.92 billion and gross profit down 8.8% to RMB 2.32 billion. Net profit fell 20.5% to RMB 939.5 million, while ba...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.